{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:40:45Z","timestamp":1785156045044,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40744-023-00586-6","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T02:01:47Z","timestamp":1691805707000},"page":"1385-1398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis"],"prefix":"10.1007","volume":"10","author":[{"given":"Jessica A.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ostor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"issue":"10","key":"586_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"586_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"586_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47(3):343\u201350.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"586_CR4","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","volume":"59","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane GJ, Pathan E, Jones GT, Dean LE. Predicting response to anti-TNFalpha therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford). 2020;59(9):2481\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"586_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40744-016-0038-y","volume":"3","author":"KA Betts","year":"2016","unstructured":"Betts KA, Griffith J, Song Y, et al. Network meta-analysis and cost per responder of tumor necrosis factor-alpha and interleukin inhibitors in the treatment of active ankylosing spondylitis. Rheumatol Ther. 2016;3(2):323\u201336.","journal-title":"Rheumatol Ther"},{"issue":"9","key":"586_CR6","first-page":"1008","volume":"28","author":"A Ogdie","year":"2022","unstructured":"Ogdie A. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. J Manag Care Spec Pharm. 2022;28(9):1008\u201320.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"586_CR7","first-page":"187","volume":"10","author":"MJ Bergman","year":"2023","unstructured":"Bergman MJ, Zueger P, Patel J, et al. Clinical and economic benefit of achieving disease control in psoriatic arthritis and ankylosing spondylitis: a retrospective analysis from the OM1 Registry. Rheumatol Ther. 2023;10(1):187\u201399.","journal-title":"Rheumatol Ther"},{"issue":"9","key":"586_CR8","first-page":"1008","volume":"28","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Hwang M, Veeranki P, et al. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. J Manag Care Spec Pharm. 2022;28(9):1008\u201320.","journal-title":"J Manag Care Spec Pharm"},{"key":"586_CR9","unstructured":"RINVOQ\u00ae (upadacitinib) receives its sixth U.S. FDA approval [press release]. Accessed 22 Feb 2023."},{"key":"586_CR10","unstructured":"U.S. FDA approves Pfizer\u2019s XELJANZ\u00ae (tofacitinib) for the treatment of active ankylosing spondylitis [press release]. Accessed 22 Feb 2023."},{"key":"586_CR11","unstructured":"European Commission approves AbbVie's RINVOQ\u2122 (upadacitinib) for the treatment of psoriatic arthritis and ankylosing spondylitis [press release]. Accessed 25 Jan 2021."},{"key":"586_CR12","unstructured":"Pfizer\u2019s XELJANZ\u00ae (tofacitinib) receives marketing authorization in the European Union for the treatment of active ankylosing spondylitis [press release]. Accessed 18 Nov 2021."},{"issue":"3","key":"586_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40744-019-0165-3","volume":"6","author":"P Mease","year":"2019","unstructured":"Mease P, Walsh JA, Baraliakos X, et al. Translating improvements with ixekizumab in clinical trial outcomes into clinical practice: ASAS40, pain, fatigue, and sleep in ankylosing spondylitis. Rheumatol Ther. 2019;6(3):435\u201350.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"586_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","volume":"55","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, Joshi A, Pangan AL, et al. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2016;55(1):80\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"586_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/rheumatology\/24.3.242","volume":"24","author":"HSG The","year":"1985","unstructured":"The HSG, Steven MM, van Der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. B J Rheumatol. 1985;24:242\u20139.","journal-title":"B J Rheumatol"},{"key":"586_CR16","unstructured":"AbbVie Inc. Rinvoq\u00ae prescribing information. Updated October 2022."},{"key":"586_CR17","unstructured":"Eli Lily and Company. TALTZ\u00ae prescribing information. Updated March 2016."},{"key":"586_CR18","unstructured":"Janssen Biotech Inc. SIMPONI\u00ae prescribing information. Updated September 2019."},{"key":"586_CR19","unstructured":"Novartis Pharmaceuticals Corporation. COSENTYX\u00ae prescribing information. Updated May 2021."},{"key":"586_CR20","unstructured":"Amgen Inc. ENBREL\u00ae prescribing information. Updated August 2020."},{"key":"586_CR21","unstructured":"Pfizer Inc. XELJANZ\u00ae prescribing information. Updated January 2022."},{"key":"586_CR22","unstructured":"AbbVie Inc. A. HUMIRA\u00ae prescribing information. Updated December 2021."},{"key":"586_CR23","unstructured":"Merative. Micromedex Solutions 2020. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian. Accessed 31 Mar 2020."},{"key":"586_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651","volume-title":"Network meta-analysis for decision-making","author":"S Dias","year":"2018","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Network meta-analysis for decision-making. New York: Wiley; 2018."},{"key":"586_CR25","doi-asserted-by":"publisher","first-page":"566160","DOI":"10.3389\/fmed.2020.566160","volume":"7","author":"JC Wei","year":"2020","unstructured":"Wei JC, Tsou HK, Leong PY, Chen CY, Huang JX. Head-to-head comparison of etanercept vs. adalimumab in the treatment of ankylosing spondylitis: an open-label randomized controlled crossover clinical trial. Front Med (Lausanne). 2020;7:566160.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"586_CR26","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/1756-185X.13635","volume":"22","author":"D Kim","year":"2019","unstructured":"Kim D, Kim H, Cho S, Park MC. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective. Int J Rheum Dis. 2019;22(9):1630\u20137.","journal-title":"Int J Rheum Dis"},{"key":"586_CR27","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 3: Heterogeneity\u2014subgroups, meta-regression, bias, and bias-adjustment. National Institute for Health and Clinical Excellence. 2011."},{"key":"586_CR28","unstructured":"Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 4: evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. National Institute for Health and Clinical Excellence. 2011."},{"key":"586_CR29","unstructured":"National Institute for Health and Care Excellence. Secukinumab for active ankylosing spondylitis after treatment with nonsteroidal anti-inflammatory drugs or TNF-alpha inhibitors [TA407]. London, UK. 2016."}],"updated-by":[{"DOI":"10.1007\/s40744-023-00626-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000}}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00586-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T07:20:42Z","timestamp":1701242442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00586-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00586-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40744-023-00626-1","asserted-by":"object"}]},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40744-023-00626-1","URL":"https:\/\/doi.org\/10.1007\/s40744-023-00626-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}